|
|
| | Urease-IN-11 Basic information |
| Product Name: | Urease-IN-11 | | Synonyms: | Urease-IN-11;7H-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazine, 6-[1,1′-biphenyl]-4-yl-3-(3-pyridinyl)- | | CAS: | 517906-12-6 | | MF: | C21H15N5S | | MW: | 369.44 | | EINECS: | | | Product Categories: | | | Mol File: | 517906-12-6.mol |  |
| | Urease-IN-11 Chemical Properties |
| Melting point | 204-205 °C | | Boiling point | 621.572±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.358±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 2.428±0.12(predicted) |
| | Urease-IN-11 Usage And Synthesis |
| Uses | Urease-IN-11 (Compound 6e) is a competitive urease inhibitor (IC50)=10.41 μM). Urease-IN-11 can be used to study diseases such as urease-related gastritis and peptic ulcer[1]. | | References | [1] Ullah S, et al. Urease inhibitory potential of pyridine-containing triazolothiadiazole and triazolothiadiazine scaffolds for the treatment of ulceration and kidney stone: in vitro screening, kinetics mechanism, and in silico computational analysis. J Biomol Struct Dyn. 2023 Dec 28:1-10. DOI:10.1080/07391102.2023.2291542 |
| | Urease-IN-11 Preparation Products And Raw materials |
|